Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2020-05-06
|
| gptkbp:ATCCode |
L01EX19
|
| gptkbp:CASNumber |
1029712-80-8
|
| gptkbp:chemicalFormula |
C24H25FN6O3
|
| gptkbp:genericName |
gptkb:capmatinib
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tabrecta
|
| gptkbp:indication |
MET exon 14 skipping mutation-positive NSCLC
|
| gptkbp:legalStatus |
Rx-only
|
| gptkbp:manufacturer |
gptkb:Novartis
|
| gptkbp:mechanismOfAction |
MET inhibitor
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting fatigue decreased appetite peripheral edema increased creatinine |
| gptkbp:target |
gptkb:MET_receptor
|
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
|
| gptkbp:bfsParent |
gptkb:NOVN
|
| gptkbp:bfsLayer |
5
|